[Pharmacological studies on schizandra fruits. III. Effects of wuweizisu C, a lignan component of schizandra fruits, on experimental liver injuries in rats].
The effects of wuweizisu C, a lignan component of schizandra fruits, on liver injuries induced by carbon tetrachloride (CCl4), d-galactosamine and dl-ethionine were investigated by means of serum-biochemical and histopathological examinations in rats. Pretreatment or combined administration of wuweizisu C dose-dependently reduced the elevation of serum transaminase activity and histological changes such as fatty degeneration, cell necrosis, inflammatory cell infiltration, etc., which were caused by the single administration of 1 ml/kg, p.o., or the repeated administration of 0.2 ml/kg, s.c., daily for 4 days of CCl4, respectively. The effects of wuweizisu C on the liver injuries induced by a low dose (200 mg/kg, i.p.) and a high dose (400 mg/kg, i.p.) of d-galactosamine were compared with those of uridine. Wuweizisu C significantly lowered the rise of serum transaminase activity after the administration of a low dose of d-galactosamine in the serum-biochemical analysis. A tendency was also shown to inhibit cell necrosis and inflammatory cell infiltration caused by both doses of d-galactosamine in the histopathological examination. On the other hand, uridine markedly repaired the serum-biochemical and histopathological changes after the administrations of both doses of d-galactosamine. Also wuweizisu C cured the liver injury by the repeated administration of 150 mg/kg, i.p., daily for 4 days of d-galactosamine. After the repeated administration of 250 mg/kg, s.c., daily for 4 days of ethionine, liver cell atrophy, diffuse fatty degeneration and decrease of serum triglyceride were observed, but not cell necrosis. Wuweizisu C dose-dependently inhibited fatty degeneration and decrease of serum triglyceride. These findings suggest that wuweizisu C can be protective and/or therapeutic on hepatocellular phenomena such as cell necrosis, fatty degeneration, inflammatory cell infiltration, etc., in human hepatitis.
Takeda
S
S
Funo
S
S
Iizuka
A
A
Kase
Y
Y
Arai
I
I
Ohkura
Y
Y
Sudo
K
K
Kiuchi
N
N
Yoshida
C
C
Maeda
S
S
D000818:Animals; D002252:Carbon Tetrachloride Poisoning / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury; D034242:Cyclooctanes; D005001:Ethionine / Q000037:antagonists & inhibitors; D005234:Fatty Liver / Q000517:prevention & control; D005688:Galactosamine / Q000037:antagonists & inhibitors; D006505:Hepatitis / Q000517:prevention & control; D017705:Lignans; D008107:Liver Diseases / Q000188:drug therapy* / Q000517:prevention & control; D008297:Male; D010936:Plant Extracts / Q000627:therapeutic use*; D010946:Plants, Medicinal; D011083:Polycyclic Compounds / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains
D034242:Cyclooctanes; D017705:Lignans; D010936:Plant Extracts; D011083:Polycyclic Compounds; D005688:Galactosamine; C031409:schizandrin C; D005001:Ethionine